The Amplify Seymour Cannabis ETF jumped 128.6% from $17.45 on 31 December 2020 to an all-time high of $39.90 on 10 February 2021. It has been boosted by hopes that more countries around the world such as Mexico and Israel will legalise the substance.
The big prize for legalisation could be in the US however, after the election of US president Joe Biden raised hopes of an end to federal cannabis prohibition. At present, the drug is legal in some form in 47 US states and fully legal in 17.
There is great potential in the US where legal cannabis sales, both consumer and medical, hit $17.5bn in 2020 and are forecast to hit $41.3bn in 2026.
Forecasted valuation of cannabis sales in 2026
However, the Amplify Seymour Cannabis ETF’s price fell to $22.81 on 13 May. This could have been down to investors coming that the realisation that legislation may be more of a drawn-out affair than first anticipated back in January, when Biden was inaugurated.
A recent recovery in the Amplify Seymour Cannabis ETF’s share price to $26.04 at the close on 28 May has been driven by US Senate majority leader Chuck Schumer’s promise of upcoming legislation and the House of Representatives passing the SAFE Banking Act providing safe harbour for banks that service the cannabis industry.
The actively managed Amplify Seymour Cannabis ETF [CNBS] invests in what it describes as the “fast-developing global cannabis industry”.
It covers sectors including medical cannabis use, agricultural technology and cannabis-infused products, such as chocolate.
The ETF, launched on 23 July 2019, has net assets of $146.6m and, according to Yahoo Finance, a year-to-date daily return of 31.05%.
Valuation of the Amplify Seymour Cannabis ETF's net assets
This compares with the 11.02% year-to-date return of the AdvisorShares Pure Cannabis ETF [YOLO]. The Amplify Seymour Cannabis ETF has 33 holdings with asset manager Silver Spike [SSPK] having the biggest weighting of 7.32%, Tilray [TLRY] with 7% and Canopy Growth [CGC] at 6.16%. Other holdings include Green Thumb Industries with 5.18%.
Shares in Silver Spike Acquisition Corp — a SPAC which acquired cannabis group WM Holdings last December — climbed from $14.40 on 10 December (the day the acquisition) to a peak of $28.71 on 17 February. As of 28 May, it slipped 43.2%.
WM operates Weedmaps, an online listings marketplace helping cannabis consumers find products and WM Business, a software offering helping cannabis retailers and brands to scale up.
Shares in Tilray have increased from $9 on 4 January to $16.67 at the close on 28 May boosted by its merger with cannabis group Aphria in early May. It has also gained following a 27% climb in 2020 annual revenues to $210.5m driven by international medical and Canadian recreational sales.
Shares in Green Thumb were up from $24.90 on 4 January to $38.45 on 10 February and now sit at $29.67 at the close on 28 May.
Its first-quarter revenues rose 89.5% to $194.4m helped by demand for its medical products and Dogwalkers — pre-rolled cannabis for leisurely strolls. The company’s chief executive Ben Kovler told Forbes: “American consumers want more weed. It’s simple.”
Furthermore, Amplify is also bullish. “Amid the evolving public perception of cannabis — from largely recreational to medicinal, to both — is the creation of new markets spurred by increased demand globally. Political momentum and public pressure to legalise cannabis for medical and recreational purposes have also gained traction,” it said noted in a statement.
“Amid the evolving public perception of cannabis — from largely recreational to medicinal, to both — is the creation of new markets spurred by increased demand globally. Political momentum and public pressure to legalise cannabis for medical and recreational purposes have also gained traction” - statement from Amplify
The Amplify Seymour Cannabis ETF was also bolstered in April when it announced that it had the ability to access cannabis Multi-State Operators via total return swaps.
“We are excited to now have access to the full plant-touching US cannabis investable universe in the CNBS portfolio at a time when we believe the US market is poised for significant growth,” says Tim Seymour, portfolio manager for the fund.
Despite the bullishness, Jacob Kilby has a neutral rating on the sector. Aside from legislation hopes he believes cannabis ETFs have been lifted by the COVID-19 economy of “monetary and fiscal tailwinds”. The prospect of rising inflation could reverse that, he warns.
“Most [cannabis] firms are over leveraged fledgling ventures with big promises and negligible earnings” - Jacob Kilby
“Most [cannabis] firms are over leveraged fledgling ventures with big promises and negligible earnings,” he wrote in Seeking Alpha. “[They] make for a risky future bet, particularly if macro-economic headwinds start becoming present.”
Green Thumb, however, believes there is only one way the smoke is blowing. “Cannabis is the next great American growth story. There is a tidal wave of demand coming,” Kovler told Forbes.
Disclaimer Past performance is not a reliable indicator of future results.
CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.
The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.
CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.
*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.